| Encyclopedia of Pharmaceutical Technology: Volume 6 J Swarbrick CRC press, 2013 | 1792 | 2013 |
| The role of ligand efficiency metrics in drug discovery AL Hopkins, GM Keserü, PD Leeson, DC Rees, CH Reynolds Nature reviews Drug discovery 13 (2), 105-121, 2014 | 1162 | 2014 |
| The influence of lead discovery strategies on the properties of drug candidates GM Keserü, GM Makara nature reviews Drug Discovery 8 (3), 203-212, 2009 | 726 | 2009 |
| Expanding the medicinal chemistry synthetic toolbox J Boström, DG Brown, RJ Young, GM Keserü Nature Reviews Drug Discovery 17 (10), 709-727, 2018 | 614 | 2018 |
| Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease A Douangamath, D Fearon, P Gehrtz, T Krojer, P Lukacik, CD Owen, ... Nature communications 11 (1), 5047, 2020 | 498 | 2020 |
| Finding the sweet spot: the role of nature and nurture in medicinal chemistry MM Hann, GM Keserü Nature reviews Drug discovery 11 (5), 355-365, 2012 | 464 | 2012 |
| Hit discovery and hit-to-lead approaches GM Keserű, GM Makara Drug discovery today 11 (15-16), 741-748, 2006 | 420 | 2006 |
| GPCRdb in 2021: integrating GPCR sequence, structure and function AJ Kooistra, S Mordalski, G Pándy-Szekeres, M Esguerra, A Mamyrbekov, ... Nucleic Acids Research 49 (D1), D335-D343, 2021 | 355 | 2021 |
| Design principles for fragment libraries: maximizing the value of learnings from pharma fragment-based drug discovery (FBDD) programs for use in academia GM Keserű, DA Erlanson, GG Ferenczy, MM Hann, CW Murray, ... Journal of medicinal chemistry 59 (18), 8189-8206, 2016 | 249 | 2016 |
| Impact of lipophilic efficiency on compound quality A Tarcsay, K Nyíri, GM Keserű Journal of medicinal chemistry 55 (3), 1252-1260, 2012 | 188 | 2012 |
| Optimization of virtual screening protocols: FlexX based virtual screening for COX-2 inhibitors reveals the importance of tailoring screen parameters A Bauer, Z Kovári, GM Keserű Journal of Molecular Structure: THEOCHEM 676 (1-3), 1-5, 2004 | 184 | 2004 |
| Thermodynamics guided lead discovery and optimization GG Ferenczy, GM Keserű Drug discovery today 15 (21-22), 919-932, 2010 | 155 | 2010 |
| Pharmacologic inhibition of STAT5 in acute myeloid leukemia B Wingelhofer, B Maurer, EC Heyes, AA Cumaraswamy, A Berger-Becvar, ... Leukemia 32 (5), 1135-1146, 2018 | 151 | 2018 |
| A high throughput luminescent assay for glycogen synthase kinase-3 β inhibitors A Baki, A Bielik, L Molnár, G Szendrei, GM Keserü Assay and drug development technologies 5 (1), 75-84, 2007 | 148 | 2007 |
| Contributions of molecular properties to drug promiscuity: miniperspective Á Tarcsay, GM Keserű Journal of medicinal chemistry 56 (5), 1789-1795, 2013 | 145 | 2013 |
| Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods GM Keserü Bioorganic & medicinal chemistry letters 13 (16), 2773-2775, 2003 | 142 | 2003 |
| Validity of ligand efficiency metrics CW Murray, DA Erlanson, AL Hopkins, GM Keserü, PD Leeson, ... ACS medicinal chemistry letters 5 (6), 616-618, 2014 | 141 | 2014 |
| Recent advances in the prediction of blood–brain partitioning from molecular structure M Lobell, L Molnár, GM Keserü Journal of pharmaceutical sciences 92 (2), 360-370, 2003 | 141 | 2003 |
| Comparative evaluation of covalent docking tools A Scarpino, GG Ferenczy, GM Keserű Journal of Chemical Information and Modeling 58 (7), 1441-1458, 2018 | 138 | 2018 |
| Virtual fragment docking by Glide: a validation study on 190 protein− fragment complexes M Sandor, R Kiss, GM Keserű Journal of Chemical Information and Modeling 50 (6), 1165-1172, 2010 | 131 | 2010 |
